Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.

Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

When is Avenue Therapeutics' next earnings date?

What price target have analysts set for ATXI?

2 Wall Street analysts have issued 12-month price objectives for Avenue Therapeutics' shares. Their predictions range from $10.00 to $11.00. On average, they anticipate Avenue Therapeutics' stock price to reach $10.50 in the next year. This suggests a possible upside of 59.3% from the stock's current price. View Analyst Price Targets for Avenue Therapeutics.

What is the consensus analysts' recommendation for Avenue Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avenue Therapeutics.

Has Avenue Therapeutics been receiving favorable news coverage?

Media headlines about ATXI stock have trended very positive this week, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Avenue Therapeutics earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $6.59.

How big of a company is Avenue Therapeutics?

Avenue Therapeutics has a market capitalization of $70.30 million. The company earns $-12,250,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Avenue Therapeutics employs 2 workers across the globe.

MarketBeat Community Rating for Avenue Therapeutics (NASDAQ ATXI)

MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote "Outperform" if you believe ATXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATXI will underperform the S&P 500 over the long term. You may vote once every thirty days.